# Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

> **NCT00751179** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 161 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** rocuronium
- **DRUG:** sugammadex
- **DRUG:** succinylcholine

## Key facts

- **NCT ID:** NCT00751179
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751179, "Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00751179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*